as 12-18-2024 1:35pm EST
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Founded: | 1988 | Country: | United States |
Employees: | N/A | City: | QUEENSBURY |
Market Cap: | 387.2M | IPO Year: | N/A |
Target Price: | $21.50 | AVG Volume (30 days): | 372.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.30 | EPS Growth: | N/A |
52 Week Low/High: | $3.43 - $13.30 | Next Earning Date: | 11-08-2024 |
Revenue: | $22,644,000 | Revenue Growth: | 945.91% |
Revenue Growth (this year): | 1605.13% | Revenue Growth (next year): | 111.67% |
DCTH Breaking Stock News: Dive into DCTH Ticker-Specific Updates for Smart Investing
Business Wire
16 days ago
Simply Wall St.
16 days ago
Simply Wall St.
a month ago
GuruFocus.com
a month ago
Business Wire
a month ago
Business Wire
2 months ago
Business Wire
2 months ago
Business Wire
2 months ago
The information presented on this page, "DCTH Delcath Systems Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.